时间:2021-02-03 14:07:50来源: 德国新闻网
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
Chinese eVTOL aircraft completes test flight in Shanghai
2024-05-15Nation's self-developed satellite to launch service in HKSAR
2024-05-10China's third aircraft carrier begins its maiden sea trial
2024-05-04People in Tangshan welcome destroyer named after the city
2024-04-26Air China prepares to resume four more international routes
2024-04-23PLA lawfully responds to U.S. aircraft flying through Taiwan Strait
2024-04-18China issues guideline to raise annual food yield
2024-04-10China's largest land port handles over 5 mln metric tons of imports and exports in Q1
2024-04-04